British American Tobacco (BAT) has released new results from one of the largest ever vapour product studies which analysed BAT’s flagship vapour brand Vuse.
The study, published in the journal of Internal and Emergency Medicine, compared clinical measurements from exclusive Vuse consumers with smokers. The results of the study show that “participating Vuse consumers had favourable differences in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) relevant to smoking-related diseases when compared to smokers,” BAT said.
According to the study, Vuse users have shown significantly lower biomarkers of exposure for priority cigarette smoke toxicants as defined by the World Health Organization (WHO). The data also showed favourable differences between Vuse consumers and smokers across all biomarkers of potential harm measured, with three being statistically significant.
Dr James Murphy, Director, Research and Science at BAT, said: “Vaping continues to grow in importance, as adult smokers seek reduced-risk alternative nicotine products. That is why these results are so important for Vuse, BAT and consumers, as they allow us to better understand the positive real-world impact of vaping compared to smoking. The research shows a clear difference between those using Vuse compared to smokers and reinforces the reduced risk potential and role of vapour in Tobacco Harm Reduction.”

Based on the biomarkers measured, compared to smokers, Vuse consumers using the product exclusively showed:
• Significantly lower levels of all measured biomarkers of exposure to priority cigarette smoke toxicants, as defined by the WHO.
• Significant favourable differences in three biomarkers of potential harm linked to the development of cardiovascular diseases (11-dTX B2, COHb and sICAM-1)
• Lower levels of biomarkers of potential harm (WBC and 8-epi-PGF2α) for general inflammation and oxidative stress and
• Favourable differences in a biomarker of potential harm (HDL) relevant to CVD
• Favourable differences in a biomarker of potential harm (FeNO) relevant to lung health

This clinical study of participating Vuse consumers, smokers, former smokers and never smokers provides comprehensive analysis of 17 biomarkers of exposure (BoE) to priority cigarette smoke toxicants, biomarkers of potential harm (BoH) and physiological measures relevant to cardiovascular conditions, respiratory diseases and cancer.
Participants were based in the UK, aged between 19-55 years old, and in good general health. Four different groups were enrolled and studied.

Read more here